摘要
目的探究扶正解毒汤联合督脉灸治疗肺脾气虚证晚期非小细胞肺癌患者的效果。方法2020年1月2022年1月扬州大学医学院海安临床学院收治的82例晚期非小细胞肺癌患者,采用随机数字表法将其分为对照组和研究组,各41例。对照组采用紫杉醇联合卡铂治疗,研究组在对照组基础上采用督脉灸联合扶正解毒汤治疗。治疗2个月后,比较两组中医证候评分、免疫炎症因子水平[白细胞介素-6(IL-6)、免疫球蛋白A(IgA)]及不良反应。结果治疗前,两组主证积分、次证积分、IL-6、lg-A比较,差异无统计学意义(P>0.05)。治疗后,两组主证积分、次证积分、IL-6均降低,且研究组低于对照组,差异有统计学意义(P<0.05);两组IgA水平较治疗前均升高,且研究组高于对照组,差异有统计学意义(P<0.05)。研究组临床疗效优于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论扶正解毒汤联合督脉灸治疗晚期非小细胞肺癌,更有助于患者的调节免疫炎症因子表达,临床效果优越。
Objective To explore the effect of Fuzheng Jiedu Decoction combined with dumai moxibustion in the treatment of non-small cell lung cancer patients in the stage of lung and spleen deficiency syndrome.Methods From January 2020 to January 2022,82 patients with advanced non-small cell lung cancer admitted to were divided into two groups by random number table method,with 41 cases in each group.The control group was treated with Paclitaxel+Carboplatin,and the study group was treated with dumai moxibustion and Fuzheng Jiedu Decoction on the basis of the control group.After two months of treatment,the scores of traditional Chinese medicine syndromes,levels of immune inflammatory factors(interleukin-6[IL-6],immunoglobulin A[IgA])and adverse reactions of the two groups were compared.Results Before treatment,there were no significant differences between the two groups in main syndrome score,secondary syndrome score,IL-6,and IgA(P>0.05).After treatment,the main syndrome score,secondary syndrome score and IL-6 of the two groups decreased,and the study group was lower than the control group,with a statistically significant difference(P<0.05).The levels of IgA in the two groups were higher compared with before treatment,and the study group was higher than the control group(P<0.05).The clinical effect in the study group was better than that in the control group,with a statistically significant difference(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Fuzheng Jiedu Decoction combined with dumai moxibustion in the treatment of advanced non-small cell lung cancer is more helpful for the patients to regulate the expression of immune inflammatory factors,and the clinical effect is superior.
作者
黄开红
王亚军
练剑锋
戴其军
HUANG Kaihong;WANG Yajun;LIAN Jianfeng;DAI Qijun(Department of Oncology,Haian Clinical College,Yangzhou University Medical School,Jiangsu Province,Haian 226600,China;Department of Acupuncture,Haian Clinical College,Yangzhou University Medical School,Jiangsu Province,Haian 226600,China;Department of Internal Medicine,Haian Clinical College,Yangzhou University Medical School,Jiangsu Province,Haian 226600,China)
出处
《中国医药导报》
CAS
2023年第22期128-131,共4页
China Medical Herald
基金
江苏省自然科学基金资助项目(BK20191211)。
关键词
非小细胞肺癌
扶正解毒汤
督脉灸
炎症
免疫
Non-small cell lung cancer
Fuzheng Jiedu Decoction
Dumai moxibustion
Inflammation
Immune
